Work

Randomized phase II study of FOLFOX +/- MET inhibitor, onartuzumab (O), in advanced gastroesophageal adenocarcinoma (GEC).

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.3_suppl.2

Authors: Manish A. Shah, Jae Yong Cho, Iain Tan Bee Huat, Niall C. Tebbutt, Chia-Jui Yen, Alice Kang, David S. Shames, Lilian Bu, Yoon-Koo Kang

Institutions: NewYork–Presbyterian Hospital, Gangnam Severance Hospital, National Cancer Centre Singapore, Austin Health, National Cheng Kung University Hospital, Genentech, Roche (China), Asan Medical Center, University of Ulsan

Language: English

Topic: Gastric Cancer Management and Outcomes

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1788635309

Cites:

Cited by: 41

Related to: 10